ABHD6 Knockout NCI-H1703 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the NCI-H1703 human lung squamous cell carcinoma line. These polyclonal cells carry a targeted disruption of the ABHD6 gene, which encodes a serine hydrolase involved in endocannabinoid degradation. The knockout model is generated using CRISPR/Cas9 technology to introduce loss-of-function mutations in the ABHD6 locus, creating a mixed population of edited cells suitable for studying the gene’s role in cancer biology and signaling.
NCI-H1703 is a well-characterized cell line isolated from a non-small cell lung carcinoma (NSCLC) of squamous origin. It exhibits epithelial morphology and is widely employed as a model for human lung squamous cell carcinoma. This cell line retains key oncogenic features of NSCLC, including aberrant signaling through growth factor pathways, and is commonly used to investigate tumor cell proliferation, migration, and drug sensitivity. The ABHD6 knockout in this context provides a relevant platform for examining endocannabinoid modulation in lung cancer.
ABHD6 is a serine hydrolase that selectively hydrolyzes the endocannabinoid 2-arachidonoylglycerol (2-AG), thereby regulating cannabinoid receptor signaling. Under normal conditions, ABHD6 degrades 2-AG at the postsynaptic membrane, attenuating activation of cannabinoid receptors CNR1 and CNR2. Downstream of cannabinoid receptors, signaling cascades include the mitogen-activated protein kinase (MAPK) pathway, the phosphoinositide 3-kinase (PI3K)/AKT pathway, and modulation of prostaglandin synthesis. ABHD6 activity thus controls the availability of 2-AG, which can also be metabolized by monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH), placing ABHD6 at a critical node in glycerolipid metabolism and endocannabinoid tone.
Knockout of ABHD6 in NCI-H1703 cells is expected to elevate 2-AG levels, leading to sustained cannabinoid receptor activation. In NSCLC, the endocannabinoid system has been implicated in regulating cell proliferation, apoptosis, and motility. Enhanced CNR1/CNR2 signaling can influence MAPK and AKT pathways, which are frequently dysregulated in lung squamous cell carcinoma. This polyclonal knockout model enables researchers to dissect how loss of ABHD6 alters oncogenic signaling networks, potentially revealing tumor-suppressive or oncogenic roles of the endocannabinoid axis in a human lung cancer background.
These polyclonal knockout cells are suited for a range of functional studies, including cell proliferation, migration, and colony formation assays, as well as drug response profiling against chemotherapeutics or cannabinoid receptor modulators. They facilitate detailed signaling analyses by Western blot for phosphorylated ERK or AKT, RT-qPCR for downstream gene expression, and immunofluorescence for protein localization. Direct measurement of 2-AG by LC-MS/MS or CB1-dependent cAMP assays can link biochemical changes to phenotypic outcomes. This model is a versatile tool for cancer signaling research and endocannabinoid pharmacology. For further details, please contact Ascent Research.
